ACE Report Cover
75 mg risedronate once-monthly appears well tolerated in Japanese osteoporosis patients
Language
Download
Cite
+ Favorites
Language
Download
Cite
+ Favorites
AceReport Image
GENERAL ORTHOPAEDICS
75 mg risedronate once-monthly appears well tolerated in Japanese osteoporosis patients .
Verified
This report has been verified by one or more authors of the original publication.

Efficacy, tolerability and safety of once-monthly administration of 75 mg risedronate in Japanese patients with involutional osteoporosis: A comparison with a 2.5 mg once-daily dosage regimen

Bone. 2014 Feb;59:44-52. doi: 10.1016/j.bone.2013.10.017. Epub 2013 Oct 29.

852 Japanese patients with involutional osteoporosis were randomized to receive 75 mg oral risedronate once-monthly or 2.5 mg oral risedronate once-daily, with the purpose of comparing the efficacy, tolerability, and safety of both treatment options. Upon analysis, results indicated that 75 mg risedronate tablets taken once a month achieved similar bone mineral density and fracture rates compared to 2.5 mg risedronate tablets taken once a day. Urinary NTX/CRN and CTX/CRN bone markers decreased significantly in both groups, but resulted in a more pronounced reduction in the 2.5 mg once-daily risedronate group, while acute phase reaction adverse events were higher in the 75 mg once-monthly risedronate group.

Unlock the Full ACE Report

You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now

Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics

Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics

Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions

Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics

Or upgrade today and gain access to all OrthoEvidence
content for as little as $1.99 per week.
0 of 4 monthly FREE articles unlocked
You've reached your limit of 4 free articles views this month

Access to OrthoEvidence for as little as $1.99 per week.

Stay connected with latest evidence. Cancel at any time.
  • Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
  • Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
  • Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Upgrade
Welcome Back!
Forgot Password?
Start your FREE trial today!

Account will be affiliated with


OR
Forgot Password?

OR
Please check your email

If an account exists with the provided email address, a password reset email will be sent to you. If you don't see an email, please check your spam or junk folder.

For further assistance, contact our support team.

Translate ACE Report

OrthoEvidence utilizes a third-party translation service to make content accessible in multiple languages. Please note that while every effort is made to ensure accuracy, translations may not always be perfect.

Cite this ACE Report

OrthoEvidence. 75 mg risedronate once-monthly appears well tolerated in Japanese osteoporosis patients. ACE Report. 2015;4(4):55. Available from: https://myorthoevidence.com/AceReport/Show/75-mg-risedronate-once-monthly-appears-well-tolerated-in-japanese-osteoporosis-patients

Copy Citation
Please login to enable this feature

To access this feature, you must be logged into an active OrthoEvidence account. Please log in or create a FREE trial account.

Premium Member Feature

To access this feature, you must be logged into a premium OrthoEvidence account.

Share this ACE Report